At the 61st ASH Annual Meeting & Exposition, Alexey Danilov discusses his presentation: Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management.
1. What have been the most important recent advances in the use of BTK inhibitors in B-cell malignancies? (0:05)
2. What factors should be considered when selecting the most appropriate BTK inhibitors for an individual? (1:27)
3. What are the major obstacles to the first-line use of BTK inhibitors in B-cell malignancies and how can these be overcome? (3:12)
4. What are likely to be the future challenges and research directions in the use of BTK inhibitors for B-cell malignancies? (4:50)
Alexey Danilov is a consult for Janssen, Pharmacyclics, AstraZeneca, Beigene, Verastem, Genentech, Gilead, Nurix, Curis and TG Therapeutics. He has received research funding from AstraZeneca, Gilead, Genentech, Verastem, BMS and Bayer.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematological Malignancies
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!